IPOL is used for primary and booster vaccination of infants, children and adults to protect against infection with Type 1, Type 2 and Type 3 polioviruses causing poliomyelitis.
Act-HIB™ is used for primary and booster vaccination of infants and children up to their 5th birthday to protect against disease caused by Haemophilus influenzae type b.The vaccine is also used for primary vaccination of children aged 5 years of age and over and adults with some chronic medical conditions. Act-HIB™ is licensed for use in infants and children 2 months to 5 years of age. It is used out of licensure in children 5 years of age and over and adults as there is no alternative vaccine available in New Zealand for these age groups. When children/individuals are older than the age to which the vaccine is licensed, use will be outside of current licensure. No safety concerns are expected for use in older age groups.
ADT™ Booster is used for primary and booster vaccination of children 7 years of age and over and adults to protect against tetanus and diphtheria. An alternative vaccine called Boostrix®, which protects against tetanus, diphtheria and pertussis (whooping cough), can be substituted for one, two or all three doses of the primary vaccinations in these age groups. Both ADT™ Booster and Boostrix® are licensed as booster vaccines. They are used for primary vaccination out of licensure as there is no alternative primary vaccination strength vaccine available in New Zealand for these age groups. When the vaccine is used for a primary vaccination course, use will be outside of current licensure. No safety concerns are expected with use in these circumstances.
Infanrix®-IPV is used for primary and booster vaccination of infants and children up to their 7th birthday to protect against diphtheria, tetanus, pertussis and poliomyelitis.
Gardasil® is funded for use for primary immunisation of girls from 12 years of age and young women to protect them from four types of human papillomavirus infection. Gardasil® is not funded but can be used for primary immunisation of females who are not eligible for funded vaccine and within the age group of 9 through 45 years and males aged 9 through 26 years to protect them from four types of human papillomavirus infection.
The Institute of Environmental Science & Research Limited (ESR)Sexually transmitted infections in New Zealand 2011 Surveillance Report identified decreasing numbers of new genital warts cases between 2008 and 2011, most notable in 2010 and 2011 and in females aged 15-19 years, corresponding with commencement of the HPV immunisation programme. The Genital Warts pages from the full report are available here. The full ESR report is available from the ESR Public Health Surveillance website.
A short YouTube DVD, The Story of HPV (Human Papillomavirus), provides information for women, parents and caregivers, health workers and students planning to work in the health sector about the human papillomavirus, the Gardasil® vaccine that helps to protect against HPV, and the importance of cervical screening and practising safer sex in protecting women's health.
Boostrix® is used for booster vaccination of adolescents aged 11 years and pregnant women between 28-38 weeks gestation to protect against diphtheria, tetanus and pertussis (whooping cough).
*After immunisation protection against pertussis takes up to two weeks to develop. Whilst immunisation between 38-40 weeks gestation is still safe for mother and baby later immunisation means the newborn may still be exposed to the disease by their mother on delivery and/or during the first two weeks of life. The PHARMAC decision to limit funded Boostrix® to 28-38 weeks gestation maximises the benefit of immunisation against pertussis whilst being accountable for the use of public funds. Pregnant women can choose to purchase Boostrix® privately after 38 weeks gestation or at any time after delivery.
Boostrix® is licensed for use in children 10 years of age and over and adults as a booster vaccine. Boostrix® can be used, out of licensure in children from 7 years of age and adults, for one or all three doses of a primary course of tetanus and diphtheria vaccination, so as to provide protection from pertussis (whooping cough). There is no alternative vaccine that provides protection from pertussis available in New Zealand for this age group.
When children are younger than the age to which the vaccine is licensed, and when the vaccine is used for a primary vaccination course, use will be outside of current licensure and parents/guardians/individuals must be fully informed of this. There are not expected to be any safety concerns for use in these circumstances.